Shilpa Medicare Ltd

Shilpa Medicare Reports Record Quarterly Revenue of ₹411 Cr 📈

• Highest quarterly revenue of ₹411 crores, up 28% YoY

• 9-month revenue at ₹1,110 crores, up 14% YoY

• Formulation revenue surged 50% YoY to ₹177 crores

• API business grew 11% including captive use

• Highest quarterly EBITDA of ₹115 crores, up 41% YoY

• EBITDA margin improved to 28% from 26%

• PAT for Q3 was ₹55 crores (adjusted for ₹13 crores exceptional item)

• 9-month PAT nearly doubled YoY

• New peptide manufacturing facility planned with ~₹40 crores capex

• EMA approval for transdermal patch Rotigotine with launch planned in Q1 FY27

• Semaglutide API validation batches to complete by Q4 FY26/Q1 FY27

• Aflibercept Phase III submission planned H1 FY27

• First ADC product to enter human studies FY27

• ROCE improved to over 17% in 9M FY26, up from 3.5% in FY23